DAPLE Modulation for Cancer Progression Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack a clear understanding of how non-canonical Wnt signaling is dysregulated during cancer progression and lack tools to effectively modulate the Wnt receptor protein in cells, making it difficult to target for therapeutic interventions.
Innovation Solution
The discovery and characterization of DAPLE, a novel non-receptor GEF for trimeric G proteins, which works synergistically with Wnt pathway receptors to enhance PI3K and β-Catenin signaling, providing a molecular interface to modulate aberrant signaling downstream of Wnt-RTK pathways, and methods for inhibiting or activating its isoforms to treat cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-canonical Wnt signaling is inhibited to suppress tumorigenesis, then cancer initiation is reduced, but cancer invasion and metastasis are enhanced
Solution Approach 1:
The patent applies temporal dynamics by switching the modulation strategy for DAPLE at different stages of cancer progression. In early stages, DAPLE is inhibited to suppress tumorigenesis; in late stages, DAPLE is activated to enhance invasion and metastasis. This time-dependent dynamic approach resolves the contradiction by adapting the intervention strategy to the specific phase of cancer development.
2Reliability
If Wnt pathway receptors are targeted for therapeutic intervention, then cancer progression is inhibited, but the lack of clear understanding of non-canonical Wnt signaling dysregulation limits effective modulation
Solution Approach 1:
The patent identifies DAPLE as a critical intermediary molecule that mediates non-canonical Wnt signaling downstream of Frizzled receptors. By targeting DAPLE rather than the receptors directly, the patent provides a more specific therapeutic intervention point that can modulate non-canonical Wnt signaling without completely blocking Wnt pathway activity. This intermediary approach fills the knowledge gap by providing a concrete molecular target for therapeutic intervention.
3Reliability
If DAPLE is selectively inhibited in early cancer stages, then tumorigenesis is suppressed, but the mechanism requires precise temporal control to avoid enhancing later invasion and metastasis
Solution Approach 1:
The patent exploits parameter changes in DAPLE expression and activity during cancer progression. By detecting changes in DAPLE levels or signaling activity as biomarkers, the patent enables temporal control of therapy without requiring complex external control mechanisms. The natural progression of cancer creates inherent parameter changes that guide when to inhibit versus activate DAPLE.
Data Source
AI summary
The invention provides DAPLE as a novel regulator of G protein activity and its diagnostic and therapeutic use in cancer.